Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.57 |
| ▸ | CACNA1I | Q9P0X4 | 9/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838489 | 1.00 | KCNH2 (0.57) | KCNH2CACNA1ICACNA1GCHRM2HRH1 | |
| SCHEMBL21726742 | 1.00 | KCNH2 (0.57) | KCNH2CACNA1ICACNA1GCHRM2HRH1 | |
| SCHEMBL29361645 | 1.00 | KCNH2 (0.57) | KCNH2CACNA1ICACNA1GCHRM2HRH1 | |
| SCHEMBL18838325 | 0.93 | KCNH2 (0.62) | KCNH2CACNA1ICACNA1GCHRM2HRH1 | |
| SCHEMBL18838360 | 0.87 | KCNH2 (0.53) | KCNH2CACNA1ICACNA1GCHRM2HRH1 | |
| SCHEMBL29363903 | 0.87 | KCNH2 (0.53) | KCNH2CACNA1ICACNA1GCHRM2HRH1 | |
| SCHEMBL29364436 | 0.86 | CACNA1H (0.63) | KCNH2CACNA1ICACNA1GCACNA1HTAS1R3 | |
| SCHEMBL18838316 | 0.86 | CACNA1H (0.63) | KCNH2CACNA1ICACNA1GCACNA1HTAS1R3 | |
| SCHEMBL18838319 | 0.86 | CACNA1H (0.63) | KCNH2CACNA1ICACNA1GCACNA1HTAS1R3 | |
| SCHEMBL18838322 | 0.86 | CACNA1H (0.63) | KCNH2CACNA1ICACNA1GCACNA1HTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744825-B2 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds | AFASCI, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20200069665-A1 | METHODS OF TREATING HYPERSENSITIVE COUGH OR ITCHING USING ION CHANNEL INHIBITORY COMPOUNDS | AFASCI, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | KCNH2 55/4885CACNA1I 1/4885CACNA1G 2/4885 |
| US-11744825-B2 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds | TRPV1, TRPA1, TRPV2 | KCNH2 56/4885CACNA1I 20/4885CACNA1G 22/4885 |
| US-20200069665-A1 | METHODS OF TREATING HYPERSENSITIVE COUGH OR ITCHING USING ION CHANNEL INHIBITORY COMPOUNDS | TRPV1, TRPA1, TRPV2 | KCNH2 56/4885CACNA1I 20/4885CACNA1G 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.